Frontiers
US$ 23.56
glp 1 drugs how do they work Weight loss – hope or hype? GLP-1 Receptor Agonists as Treatments
Description
The SOUL and FLOW trials further support these findings for oral semaglutide
All relevant data supporting the findings of this study are included within the manuscript and supplementary materials
Not everyone needs or tolerates a GLP-1
Forbes contributor Bruce Japsen reported in June 2026 that a growing share of health plans and employers are refusing to cover the drugs for weight loss, restricting coverage to diabetes indications or requiring prior authorisation hurdles that most patients cannot clear
As supply improves, these compounded versions are no longer legally allowed, making the loss temporary
